Jiangsu Aidea Pharmaceutical Co., Ltd. (688488.SS)
CNY 11.2
(2.94%)
CNY 11.2
(2.94%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -39.29 Million CNY | 85.62% |
| 2022 | -96.11 Million CNY | -1145.15% |
| 2021 | -4.94 Million CNY | -107.44% |
| 2020 | 74.71 Million CNY | 2.58% |
| 2019 | 71 Million CNY | 79.19% |
| 2018 | 30.26 Million CNY | 256.03% |
| 2017 | -27.63 Million CNY | -134.07% |
| 2016 | 34.73 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -14.52 Million CNY | 78.4% |
| 2024 Q2 | -32.14 Million CNY | -253.5% |
| 2024 Q3 | -14.18 Million CNY | 44.03% |
| 2023 Q2 | -4.61 Million CNY | -368.49% |
| 2023 FY | - CNY | 85.62% |
| 2023 Q4 | -27.51 Million CNY | -14.36% |
| 2023 Q3 | -24.05 Million CNY | -421.66% |
| 2023 Q1 | 1.71 Million CNY | 272.79% |
| 2022 Q3 | -32.84 Million CNY | 18.06% |
| 2022 FY | - CNY | -1145.15% |
| 2022 Q2 | -40.08 Million CNY | -38.24% |
| 2022 Q1 | -28.99 Million CNY | 17.72% |
| 2022 Q4 | -994.07 Thousand CNY | 96.97% |
| 2021 Q2 | -436.55 Thousand CNY | -104.09% |
| 2021 Q1 | 10.67 Million CNY | -33.15% |
| 2021 Q4 | -35.24 Million CNY | -237.86% |
| 2021 Q3 | -10.43 Million CNY | -2289.59% |
| 2021 FY | - CNY | -107.44% |
| 2020 Q2 | 25.68 Million CNY | 219.66% |
| 2020 Q1 | 8.03 Million CNY | -73.81% |
| 2020 FY | - CNY | 2.58% |
| 2020 Q4 | 15.96 Million CNY | 253.99% |
| 2020 Q3 | 4.5 Million CNY | -82.44% |
| 2019 Q4 | 30.67 Million CNY | 479.51% |
| 2019 Q2 | 19.2 Million CNY | 20.65% |
| 2019 Q1 | 15.92 Million CNY | 0.0% |
| 2019 FY | - CNY | 79.19% |
| 2019 Q3 | -8.08 Million CNY | -142.08% |
| 2018 FY | - CNY | 256.03% |
| 2017 FY | - CNY | -134.07% |
| 2016 FY | - CNY | 0.0% |